Genocea Biosciences Inc. (GNCA) Trading Down 2.2%
Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) were down 2.2% during trading on Wednesday . The company traded as low as $5.29 and last traded at $5.34, with a volume of 134,723 shares changing hands. The stock had previously closed at $5.46.
Several analysts recently commented on the company. FBR & Co reiterated a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.95.
The company has a 50 day moving average of $5.18 and a 200 day moving average of $4.68. The stock’s market capitalization is $154.70 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/genocea-biosciences-inc-gnca-trading-down-2-2.html
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative return on equity of 47.87% and a negative net margin of 5,121.17%. On average, equities analysts predict that Genocea Biosciences Inc. will post ($1.63) EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new stake in Genocea Biosciences during the first quarter valued at about $103,000. Alpine Partners VI LLC acquired a new stake in Genocea Biosciences during the second quarter valued at about $120,000. TFS Capital LLC acquired a new stake in Genocea Biosciences during the second quarter valued at about $133,000. Dimensional Fund Advisors LP acquired a new stake in Genocea Biosciences during the second quarter valued at about $143,000. Finally, Ameriprise Financial Inc. acquired a new stake in Genocea Biosciences during the second quarter valued at about $156,000. 56.49% of the stock is owned by institutional investors.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.